Every 10-Q that Pasithea Therapeutics Corp. (KTTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KTTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KTTA filings page.
Pasithea Therapeutics Corp. is a clinical-stage biotech developing treatments for RASopathies, MAPK pathway-driven tumors and CNS disorders, led by MEK inhibitor PAS-004, now in Phase 1 and Phase 1/1b trials for advanced tumors and NF1 plexiform neurofibromas. The company also has PAS-001 in discovery for schizophrenia.
For the quarter ended June 30, 2026, Pasithea reported a net loss of $5.3 million versus $3.7 million a year earlier, and a six‑month net loss of $8.1 million. Operating expenses rose as general and administrative spending reached $2.0 million and research and development climbed to $3.7 million for the quarter, reflecting expanded clinical, CMC and non‑clinical work on PAS‑004.
Cash and cash equivalents were $45.7 million at June 30, 2026, with total assets of $51.7 million and stockholders’ equity of $49.8 million. The company also has 54,828,835 paid but unexercised December 2025 pre‑funded warrants at a $0.001 exercise price. Management concluded there is no substantial doubt about the company’s ability to continue as a going concern for at least 12 months, but ongoing operations remain dependent on external financing.
Pasithea Therapeutics Corp. reported a net loss of $2.9 million for the quarter ended March 31, 2026, narrower than the prior-year loss. The company is ramping investment in its PAS-004 clinical programs while benefiting from higher interest income and warrant valuation gains.
Research and development spending rose to $2.9 million as Phase 1 trials in advanced tumors and NF1-related plexiform neurofibromas progressed. Pasithea ended the quarter with $50.4 million in cash and equivalents and working capital of about $51.2 million, and management believes this is sufficient for at least 12 months.
Pasithea Therapeutics (KTTA) filed its Q3 2025 report, highlighting ongoing clinical progress alongside tight liquidity. The company reported a net loss of $3.04 million for the quarter, driven by general and administrative expenses of $1.75 million and research and development of $1.36 million. For the nine months, net loss was $10.32 million.
Cash and cash equivalents were $4.1 million with working capital of $4.2 million as of September 30, 2025. Management stated there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Stockholders’ equity stood at $12.21 million, and the accumulated deficit was $59.9 million.
Pasithea advanced its lead MEK inhibitor PAS-004: the first-in-human dose escalation in advanced tumors continued, and the Phase 1/1b trial in adult NF1-PN expanded across sites in the U.S., Australia, and South Korea. To fund operations, the company completed a May 2025 public offering (aggregate gross proceeds including warrant exercises of approximately $6.3 million) and raised $2.01 million net via its ATM earlier in 2025. 7,443,577 shares were outstanding as of November 12, 2025.